Analysts Conflicted on These Healthcare Names: Cochlear (OtherCHEOF), Universal Health (UHS) and Vera Therapeutics (VERA)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cochlear (CHEOF – Research Report), Universal Health (UHS – Research Report) and Vera Therapeutics (VERA – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Cochlear (CHEOF)
In a report released today, David Stanton from Jefferies maintained a Buy rating on Cochlear, with a price target of A$285.00. The company’s shares closed last Tuesday at $124.94.
According to TipRanks.com, Stanton is a 4-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Cochlear with a $172.66 average price target, which is a 38.2% upside from current levels. In a report issued on March 14, TipRanks – DeepSeek also upgraded the stock to Buy with a A$193.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Universal Health (UHS)
In a report released today, Benjamin Rossi from J.P. Morgan maintained a Hold rating on Universal Health, with a price target of $235.00. The company’s shares closed last Monday at $193.47.
According to TipRanks.com, Rossi is a 3-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Universal Health with a $246.00 average price target, a 26.1% upside from current levels. In a report issued on March 10, TipRanks – xAI also downgraded the stock to Hold with a $208.00 price target.
Vera Therapeutics (VERA)
J.P. Morgan analyst Anupam Rama maintained a Buy rating on Vera Therapeutics today and set a price target of $90.00. The company’s shares closed last Monday at $40.05.
According to TipRanks.com, Rama is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $84.78 average price target, which is a 109.0% upside from current levels. In a report issued on March 10, Wolfe Research also upgraded the stock to Buy with a $88.00 price target.
